# M18-803 T-PLL

## Inclusion criteria

 Adequate liver, kidney and hematology function per laboratory values as described in the protocol.
 Diagnosis of T-cell prolymphocytic leukemia (T-PLL) that requires treatment.
 Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
 Negative for human T-cell lymphotropic virus, type 1.
 Received prior alemtuzumab (unless unsuitable or unavailable).
 Has no malignancies other than T-PLL that:
o Currently require systemic therapies;
o Were not previously treated with curative intention (unless the malignant disease is in a stable remission due to the discretion of the treating physician); or
o Developed signs of progression after curative treatment

## Exclusion criteria

 History of or current decompensated cirrhosis including Child-Pugh class B or C, ascites, hepatic encephalopathy, or variceal bleeding.
 Has human T-cell lymphotropic virus, type 1.
 Prior allogeneic stem cell transplant within 6 months of study drug administration and requirement for graft versus host therapy.
 Has an uncontrolled or active infection.
 Previously treated with a B-cell lymphoma (BCL)-2 inhibitor.
 Received a prohibited therapy within the specified time frame as described in the protocol.